Headquartered in Batiment Iro, ChÂtillon Fiscal year ends December NASDAQ: DBVT dbv-technologies.com
DBV Technologies is a late-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. The company's proprietary VIASKIN patch technology uses epicutaneous immunotherapy (EPIT), a non-invasive approach that introduces microgram amounts of biologically active compounds through intact skin to re-educate the immune system and promote desensitization to allergens. DBV's lead product candidate is the VIASKIN Peanut Patch, currently under development for peanut allergy in multiple age groups: children aged 4 through 7 years (for which a BLA submission to the FDA is anticipated in Q3 2026), toddlers aged 1 through 3 years (COMFORT Toddlers safety study), and infants aged 6 through 12 months (THRIVE efficacy study). The company is pre-revenue and is actively building U.S. commercial infrastructure across Medical Affairs, Sales, Market Access, Marketing, Account Management, and Pharmacovigilance functions in anticipation of a potential product launch. DBV's ordinary shares trade on Euronext Paris and its ADSs (each representing five ordinary shares) trade on the Nasdaq Capital Market. Updated
Pre-Market Stock Futures: Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard on Friday as investors began…
Pre-Market Stock Futures: Futures are trading lower on Wednesday after an ADP report showing job losses, following a stellar day across Wall Street on Tuesday. All of the major indices finished the…
DBV Technologies is a late-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical need.
The Wall Street consensus 12-month price target for DBVT is $38.65.
